Organization | Amphastar Pharmaceuticals

Amphastar Pharmaceuticals Report issue

For profit Phase 2 Phase 3 Phase 4

Founded: Rancho Cucamonga CA United States (1996)

Status: No NME R&D (1996)

Organization Overview

First Clinical Trial

2007

NCT00635505

First Marketed Drug

1996

corticotropin (acthar)

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

AMPHASTAR PHARM | A:mphastar Pharmaceuticals, Inc. | Amphastar Pharmaceuticals, Inc. | Amphastar Pharmeceuticals, Inc. | AMPHASTAR PHARMS INC

Active Ingredients

Marketed Drugs (15)

corticotropin (acthar) (1970)

enoxaparin (lovenox) (2011)

ganirelix (2022)

glucagon (2020)

hyaluronidase (bovine) (Wydase) (2004)

isoprenaline (2018)

ketorolac (acuvail) (2004)

levobupivacaine (chirocaine) (2003)

lidocaine (xylocaine) (2003)

medroxyprogesterone (provera) (2017)

naloxone (narcan) (2023)

neostigmine (bloxiverz) (2017)

nitroprusside (nipride) (2017)

succinylcholine (anectine) (2020)

vasopressin (vasostrict) (2022)

Drugs in Phase 4 Trials (2)

albuterol (proventil) (9 trials)

epinephrine (levophed) (10 trials)

Drugs in Phase 3 Trials (1)

insulin aspart (Novolog) (1 trial)

Drugs in Phase 2 Trials (3)

histamine (1 trial)

hyaluronidase (bovine) (Wydase) (1 trial)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Anaphylaxis (Phase 4)

Asthma (Phase 3)

Bronchial Spasm (Phase 3)

Dyspnea (Phase 2)

Lung Diseases, Obstructive (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Respiratory Aspiration (Phase 4)

Respiratory Sounds (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 20
# of Trial APIs: 6